Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...

Stifel Nicolaus cut shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a hold rating in a report issued ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

We recently published an article titled Jim Cramer Discusses These 12 Stocks & Says Late Selloffs Are Deliberate. In this ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

Goldman Sachs analysts added Novo Nordisk (NVO) to the firm’s European Conviction List as part of its monthly update. Novo Nordisk’s recent ...

Gensaic partnership with Novo Nordisk, worth up to $354M, aims to develop next-generation precision therapies using novel protein design technology.

Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...

Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...